Geron Corporation $GERN Stock Position Raised by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in shares of Geron Corporation (NASDAQ:GERN) by 144.1% in the 1st quarter, Holdings Channel reports. The institutional investor owned 1,799,521 shares of the biopharmaceutical company’s stock after acquiring an additional 1,062,355 shares during the period. Renaissance Technologies LLC’s holdings in Geron were worth $2,681,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in GERN. RA Capital Management L.P. increased its holdings in Geron by 5.6% in the fourth quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock worth $84,178,000 after buying an additional 3,392,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Geron by 3.6% in the fourth quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock valued at $47,072,000 after acquiring an additional 1,237,844 shares during the last quarter. State Street Corp lifted its stake in Geron by 0.9% in the fourth quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock valued at $35,465,000 after acquiring an additional 248,508 shares during the last quarter. Vestal Point Capital LP grew its position in Geron by 8.0% in the second quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock worth $33,523,000 after acquiring an additional 1,769,660 shares in the last quarter. Finally, Eversept Partners LP grew its position in Geron by 40.2% in the fourth quarter. Eversept Partners LP now owns 17,659,983 shares of the biopharmaceutical company’s stock worth $23,311,000 after acquiring an additional 5,060,981 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Geron Price Performance

GERN opened at $1.48 on Monday. The firm has a market cap of $950.86 million, a P/E ratio of -13.45 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.16 and a current ratio of 6.91. The business has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.47. Geron Corporation has a twelve month low of $1.04 and a twelve month high of $2.01.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The firm had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. Research analysts forecast that Geron Corporation will post -0.04 EPS for the current year.

Key Stories Impacting Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Geron reported record second-quarter revenue of $57.48 million, exceeding the $55.30 million analyst consensus, with growth attributed to demand for Rytelo. The revenue beat supports the commercial potential of the company’s lead product. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Traders purchased a large volume of Geron call options, signaling that some market participants are positioning for potential upside in GERN. However, options activity does not guarantee a sustained move in the stock. Stock Traders Buy Large Volume of Geron Call Options
• Neutral Sentiment: Analyst opinions on Geron remain mixed, indicating uncertainty about the company’s earnings trajectory and the pace at which Rytelo can translate into profitability. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Geron reported a second-quarter loss of $0.02 per share, missing the $0.01-per-share loss analysts expected. Its negative net margin and continued losses highlight that the company has not yet achieved profitability. Geron: Q2 Earnings Snapshot
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026 through 2030, including estimates of a $0.05 loss for 2026, $0.02 EPS for 2027, $0.12 for 2028, $0.32 for 2029 and $0.55 for 2030. The revisions suggest weaker near- and long-term earnings expectations, likely contributing to selling pressure. HC Wainwright Geron EPS Estimates

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.